NASDAQ · GILD
Gilead Sciences Inc.
$130.52 +$1.21 (+0.94%) 1D Pre-market
Session Pulse
Pre-market
1
mentions on Wed
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
5/11
this week
Full pulse →
Key Metrics
$160.55B
Market cap
17.42×
P/E · TTM
$29.74B
Revenue · TTM
$9.22B
Net income
EPS · TTM
$7.32
Dividend yield
2.5%
Free cash flow
$10.23B
Beta · 1Y
0.34
EBITDA · TTM
$11.09B
Gross margin
—
Snapshot
Market cap$160.55B
Enterprise value$181.72B
Shares outstanding1.2B
52-wk range$108.46 – $157.29
Avg volume · 20D7.3M
Net cash
−$21.18B
Book value / share$18.68
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Gilead Sciences Inc.
IPO dateJan 22, 1992
Employees17000
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E17.42
P/S5.40
P/FCF15.69
EV/EBITDA16.38
EV/Sales6.11
Graham №$55.46
Profitability
Gross
—
Operating
36.1%
Net
31.0%
FCF
34.4%
ROE / ROIC
43.0% · 20.2%
Financial Health
Current ratio1.97
Quick ratio1.77
Debt / equity0.94
Debt / EBITDA
2.00
Net cash
−$21.18B
Working capital$9.17B
Cash Flow · TTM
Operating CF
$10.81B
Capex
−$576.00M
Free cash flow
$10.23B
Buybacks
$1.61B
Dividends paid
$4.03B
Shareholder yield
3.5%
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
$55.46 vs $130.52
Trades 2.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings